前列腺癌放疗直肠间隔物使用、急性并发症及治疗延迟
基于2016至2021年美国Merative MarketScan数据库,分析前列腺癌患者直肠水凝胶间隔物使用、置入并发症及放疗延迟。间隔物使用率从2016年0.5%升至2021年25.7%,SBRT患者2021年达50.0%;
要点
- 间隔物使用率快速上升,2021年SBRT患者达50.0%
- 放疗前并发症发生率6.4%,以泌尿生殖系统为主(5.2%)
核心结论
- 直肠间隔物在前列腺癌SBRT患者中广泛使用,置入并发症虽罕见但可延迟放疗开始。
研究设计与样本
- 回顾性数据库研究,使用Merative MarketScan数据库识别2016至2021年接受间隔物置入或单纯放疗的前列腺癌患者。
- 共捕获3732例间隔物置入,其中3650例(97.8%)后续接受放疗。
主要发现
- 间隔物使用率从前列腺癌放疗患者的0.5%(2016年)增至25.7%(2021年)。
- 2021年SBRT患者间隔物使用率最高,达50.0%。
- 放疗前并发症发生率为6.4%(n=235),其中泌尿生殖系统5.2%(n=190),胃肠道1.2%(n=43)。
- 需导管置入、膀胱镜、直肠内镜、直肠脓肿引流者分别为21例(0.6%)、15例(0.4%)、12例(0.3%)、1例(0.03%)、1例(0.03%)。
临床怎么用
- 在前列腺癌SBRT患者中可考虑使用直肠间隔物,但需告知置入并发症及可能延迟放疗的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate rectal hydrogel spacer use, placement complications, and associated radiation delays in the United States. METHODS: The Merative MarketScan Database was used to identify prostate cancer patients undergoing spacer placement or radiation alone between 2016 and 2021. Genitourinary and gastrointestinal complications and subsequent interventions that occurred after spacer placement but before radiation were captured. A 6-month window preceding spacer placement was employed to eliminate underlying diagnoses present before spacer placement. Delays in starting radiation after spacer placement were identified and categorized as more than 1, 2, or 3 months. A Cox proportional hazards model with a time-varying covariate of acute complications was used to assess the effect of complications on time-to-radiation. RESULTS: We captured 3,732 spacer placements, of which 3,650 (97.8%) underwent radiation. The use of spacers among prostate cancer radiation patients increased from 0.5% in 2016 to 25.7% in 2021. Stereotactic body radiotherapy (SBRT) patients had the highest spacer use at 50.0% in 2021. Complications occurred in 6.4% (n = 235) of patients before starting radiation. Of these, 5.2% (n = 190) were genitourinary and 1.2% (n = 43) were gastrointestinal complications. Catheterization, cystoscopy, rectal endoscopy, and rectal abscess drainage were required for 21 (0.6%), 15 (0.4%), 12 (0.3%), 1 (0.03%), and 1 (0.03%) patients, respectively. Following a complication, patients had a significantly lower risk (Hazard Ratio 0.75, 95% CI 0.66-0.86, P <.001) of starting radiation compared to before the complication. CONCLUSION: Rectal spacer use is prevalent amongst patients undergoing SBRT. While rare, spacer placement complications occur, which can delay the start of radiation therapy.
引用
- Millot JC, Balasubramanian A, Chew L, et al. Utilization, Acute Complications, and Delays in Treatment Associated With Rectal Spacers for Prostate Cancer Radiotherapy. Urology. 2025. PMID: 40609694. doi:10.1016/j.urology.2025.06.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。